A phase II study of carboplatin in adenocarcinoma of the oesophagus
Oesophageal carcinoma has a reputation for being a chemoresistant disease. However four phase II studies of cisplatin have shown a response rate of 22% in 73 patients when used as a single agent (Kelsen, 1984a). The toxicity of cisplatin may be severe with nausea, vomiting, neurological and renal da...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1988-10, Vol.58 (4), p.500-501 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 501 |
|---|---|
| container_issue | 4 |
| container_start_page | 500 |
| container_title | British journal of cancer |
| container_volume | 58 |
| creator | STEEL, A CULLEN, M. H ROBERTSON, P. W MATTHEWS, H. R |
| description | Oesophageal carcinoma has a reputation for being a chemoresistant disease. However four phase II studies of cisplatin have shown a response rate of 22% in 73 patients when used as a single agent (Kelsen, 1984a). The toxicity of cisplatin may be severe with nausea, vomiting, neurological and renal damage. Carboplatin is a cisplatin analogue which is less nephrotoxic and less neurotoxic than the parent compound and can be given to out-patients. It has some activity in oesophageal squamous cell carcinoma but has no activity in adenocarcinoma of the stomach or the cardia. The authors report a phase II study of carboplatin in patients with adenocarcinoma of the oesophagus. Toxicity was mild and manageable. Nausea and vomiting WHO grade 1 or 2 was seen after 20 of the 29 courses assessed. Severe haematological toxicity WHO grade 3 was only seen in two patients. Nephrotoxicity was mild with only one patient having a WHO grade 1 elevation of his serum creatinine. |
| doi_str_mv | 10.1038/bjc.1988.249 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2246802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78595865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-6ec3892db8fa75b451b19c17614d9b5aa30dde154332eed76c4f7d9b791c8be33</originalsourceid><addsrcrecordid>eNqFkc1LwzAYxoMoc05vXoUexJOd-WySizCGH4OBFz2HJE23StvMphX235uyMvQkBF6S5_c-POEB4BrBOYJEPJhPO0dSiDmm8gRMESM4RQLzUzCFEPIUSgzPwUUIn_EqoeATMCEwQ5TCKVgukt1WB5esVkno-nyf-CKxujV-V-mubJJ4dO4aH99s2fhaD0C3dYl3wcfVTR8uwVmhq-CuxjkDH89P78vXdP32slou1qmlEHVp5iwREudGFJozQxkySFrEY5JcGqY1gXnuEKOEYOdynlla8KhwiawwjpAZeDz47npTu9y6pmt1pXZtWet2r7wu1V-lKbdq478VxjQTEEeDu9Gg9V-9C52qy2BdVenG-T4oLphkImP_gohhJCEdIt0fQNv6EFpXHNMgqIZ2VGxHDe2o2E7Eb37_4AiPdUT9dtR1sLoqWt3YMhwxjjIppCQ_OeKYGA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15219043</pqid></control><display><type>article</type><title>A phase II study of carboplatin in adenocarcinoma of the oesophagus</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>PubMed Central</source><creator>STEEL, A ; CULLEN, M. H ; ROBERTSON, P. W ; MATTHEWS, H. R</creator><creatorcontrib>STEEL, A ; CULLEN, M. H ; ROBERTSON, P. W ; MATTHEWS, H. R</creatorcontrib><description>Oesophageal carcinoma has a reputation for being a chemoresistant disease. However four phase II studies of cisplatin have shown a response rate of 22% in 73 patients when used as a single agent (Kelsen, 1984a). The toxicity of cisplatin may be severe with nausea, vomiting, neurological and renal damage. Carboplatin is a cisplatin analogue which is less nephrotoxic and less neurotoxic than the parent compound and can be given to out-patients. It has some activity in oesophageal squamous cell carcinoma but has no activity in adenocarcinoma of the stomach or the cardia. The authors report a phase II study of carboplatin in patients with adenocarcinoma of the oesophagus. Toxicity was mild and manageable. Nausea and vomiting WHO grade 1 or 2 was seen after 20 of the 29 courses assessed. Severe haematological toxicity WHO grade 3 was only seen in two patients. Nephrotoxicity was mild with only one patient having a WHO grade 1 elevation of his serum creatinine.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1988.249</identifier><identifier>PMID: 3061440</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adenocarcinoma - drug therapy ; Aged ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carboplatin ; Chemotherapy ; Drug Evaluation ; Esophageal Neoplasms - blood ; Esophageal Neoplasms - drug therapy ; Humans ; Leukocyte Count ; Male ; Medical sciences ; Middle Aged ; Organoplatinum Compounds - therapeutic use ; Pharmacology. Drug treatments ; Platelet Count</subject><ispartof>British journal of cancer, 1988-10, Vol.58 (4), p.500-501</ispartof><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-6ec3892db8fa75b451b19c17614d9b5aa30dde154332eed76c4f7d9b791c8be33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246802/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246802/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7169899$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3061440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEEL, A</creatorcontrib><creatorcontrib>CULLEN, M. H</creatorcontrib><creatorcontrib>ROBERTSON, P. W</creatorcontrib><creatorcontrib>MATTHEWS, H. R</creatorcontrib><title>A phase II study of carboplatin in adenocarcinoma of the oesophagus</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>Oesophageal carcinoma has a reputation for being a chemoresistant disease. However four phase II studies of cisplatin have shown a response rate of 22% in 73 patients when used as a single agent (Kelsen, 1984a). The toxicity of cisplatin may be severe with nausea, vomiting, neurological and renal damage. Carboplatin is a cisplatin analogue which is less nephrotoxic and less neurotoxic than the parent compound and can be given to out-patients. It has some activity in oesophageal squamous cell carcinoma but has no activity in adenocarcinoma of the stomach or the cardia. The authors report a phase II study of carboplatin in patients with adenocarcinoma of the oesophagus. Toxicity was mild and manageable. Nausea and vomiting WHO grade 1 or 2 was seen after 20 of the 29 courses assessed. Severe haematological toxicity WHO grade 3 was only seen in two patients. Nephrotoxicity was mild with only one patient having a WHO grade 1 elevation of his serum creatinine.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carboplatin</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Esophageal Neoplasms - blood</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Count</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1LwzAYxoMoc05vXoUexJOd-WySizCGH4OBFz2HJE23StvMphX235uyMvQkBF6S5_c-POEB4BrBOYJEPJhPO0dSiDmm8gRMESM4RQLzUzCFEPIUSgzPwUUIn_EqoeATMCEwQ5TCKVgukt1WB5esVkno-nyf-CKxujV-V-mubJJ4dO4aH99s2fhaD0C3dYl3wcfVTR8uwVmhq-CuxjkDH89P78vXdP32slou1qmlEHVp5iwREudGFJozQxkySFrEY5JcGqY1gXnuEKOEYOdynlla8KhwiawwjpAZeDz47npTu9y6pmt1pXZtWet2r7wu1V-lKbdq478VxjQTEEeDu9Gg9V-9C52qy2BdVenG-T4oLphkImP_gohhJCEdIt0fQNv6EFpXHNMgqIZ2VGxHDe2o2E7Eb37_4AiPdUT9dtR1sLoqWt3YMhwxjjIppCQ_OeKYGA</recordid><startdate>19881001</startdate><enddate>19881001</enddate><creator>STEEL, A</creator><creator>CULLEN, M. H</creator><creator>ROBERTSON, P. W</creator><creator>MATTHEWS, H. R</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19881001</creationdate><title>A phase II study of carboplatin in adenocarcinoma of the oesophagus</title><author>STEEL, A ; CULLEN, M. H ; ROBERTSON, P. W ; MATTHEWS, H. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-6ec3892db8fa75b451b19c17614d9b5aa30dde154332eed76c4f7d9b791c8be33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carboplatin</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Esophageal Neoplasms - blood</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Count</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEEL, A</creatorcontrib><creatorcontrib>CULLEN, M. H</creatorcontrib><creatorcontrib>ROBERTSON, P. W</creatorcontrib><creatorcontrib>MATTHEWS, H. R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEEL, A</au><au>CULLEN, M. H</au><au>ROBERTSON, P. W</au><au>MATTHEWS, H. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of carboplatin in adenocarcinoma of the oesophagus</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>1988-10-01</date><risdate>1988</risdate><volume>58</volume><issue>4</issue><spage>500</spage><epage>501</epage><pages>500-501</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Oesophageal carcinoma has a reputation for being a chemoresistant disease. However four phase II studies of cisplatin have shown a response rate of 22% in 73 patients when used as a single agent (Kelsen, 1984a). The toxicity of cisplatin may be severe with nausea, vomiting, neurological and renal damage. Carboplatin is a cisplatin analogue which is less nephrotoxic and less neurotoxic than the parent compound and can be given to out-patients. It has some activity in oesophageal squamous cell carcinoma but has no activity in adenocarcinoma of the stomach or the cardia. The authors report a phase II study of carboplatin in patients with adenocarcinoma of the oesophagus. Toxicity was mild and manageable. Nausea and vomiting WHO grade 1 or 2 was seen after 20 of the 29 courses assessed. Severe haematological toxicity WHO grade 3 was only seen in two patients. Nephrotoxicity was mild with only one patient having a WHO grade 1 elevation of his serum creatinine.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>3061440</pmid><doi>10.1038/bjc.1988.249</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1988-10, Vol.58 (4), p.500-501 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2246802 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; Nature Journals Online; PubMed Central |
| subjects | Adenocarcinoma - drug therapy Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Carboplatin Chemotherapy Drug Evaluation Esophageal Neoplasms - blood Esophageal Neoplasms - drug therapy Humans Leukocyte Count Male Medical sciences Middle Aged Organoplatinum Compounds - therapeutic use Pharmacology. Drug treatments Platelet Count |
| title | A phase II study of carboplatin in adenocarcinoma of the oesophagus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A20%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20carboplatin%20in%20adenocarcinoma%20of%20the%20oesophagus&rft.jtitle=British%20journal%20of%20cancer&rft.au=STEEL,%20A&rft.date=1988-10-01&rft.volume=58&rft.issue=4&rft.spage=500&rft.epage=501&rft.pages=500-501&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1988.249&rft_dat=%3Cproquest_pubme%3E78595865%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15219043&rft_id=info:pmid/3061440&rfr_iscdi=true |